Marianne Labussière1, Blandine Boisselier1, Karima Mokhtari1, Anna-Luisa Di Stefano1, Anais Rahimian1, Marta Rossetto1, Pietro Ciccarino1, Olivier Saulnier1, Rosina Paterra1, Yannick Marie1, Gaetano Finocchiaro1, Marc Sanson2. 1. From Sorbonne Universités (M.L., B.B., K.M., A.-L.D.S., A.R., M.R., P.C., O.S., M.S.), UPMC Univ Paris 06, Inserm, CNRS, UM 75, U 1127, UMR 7225, ICM, Paris; Institut du Cerveau et de la Moelle épinière (ICM) (B.B., Y.M.), Plateforme de Génotypage Séquençage, Paris; Groupe Hospitalier Pitié Salpêtrière, Laboratoire de Neuropathologie R Escourolle (K.M.), Onconeurothèque (K.M., Y.M., M.S.), and Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 (A.-L.D.S., M.S.), AP-HP, Paris, France; National Neurological Institute C. Mondino (A.-L.D.S.), Pavia; Department of Neuroscience (M.R., P.C.), University of Padova; and Unit of Molecular Neuro-Oncology (R.P., G.F.), Fondazione IRCCS Carlo Besta, Milan, Italy. 2. From Sorbonne Universités (M.L., B.B., K.M., A.-L.D.S., A.R., M.R., P.C., O.S., M.S.), UPMC Univ Paris 06, Inserm, CNRS, UM 75, U 1127, UMR 7225, ICM, Paris; Institut du Cerveau et de la Moelle épinière (ICM) (B.B., Y.M.), Plateforme de Génotypage Séquençage, Paris; Groupe Hospitalier Pitié Salpêtrière, Laboratoire de Neuropathologie R Escourolle (K.M.), Onconeurothèque (K.M., Y.M., M.S.), and Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 (A.-L.D.S., M.S.), AP-HP, Paris, France; National Neurological Institute C. Mondino (A.-L.D.S.), Pavia; Department of Neuroscience (M.R., P.C.), University of Padova; and Unit of Molecular Neuro-Oncology (R.P., G.F.), Fondazione IRCCS Carlo Besta, Milan, Italy. marc.sanson@psl.aphp.fr.
Abstract
OBJECTIVE: To identify the prognostic significance of TERT promoter mutations (TERTp-mut) and their associations with common molecular alterations in glioblastomas (GBMs). METHODS: We sequenced the TERTp-mut in DNA from 395 GBMs and analyzed the results with their respective histology, genetic profile (IDH1 mutation, EGFR amplification, CDKN2A homozygous deletion, loss of chromosome 10, TP53 mutation), and overall survival (OS). RESULTS: TERTp-mut were found in 299 of 395 GBMs (75.7%) and were associated with an older age (median 59.6 years for TERTp-mut vs 53.6 years for TERT promoter wild type [TERTp-wt], p < 0.0001). TERTp-mut was an independent factor of poor prognosis (OS = 13.8 vs 18.4 months), in both IDH-mutated (OS = 13.8 vs 37.6 months, p = 0.022) and IDH-wt GBMs (OS = 13.7 vs 17.5 months, p = 0.006). TERTp-mut was associated with IDH-wt, EGFR amplification, CDKN2A deletion, and chromosome 10q loss, but not with MGMT promoter methylation. In the TERTp-wt group, OS was twice longer in EGFR-wt than in EGFR amplification GBMs (OS = 26.6 vs 13.3 months; p = 0.005). In the EGFR-wt group, patients with TERTp-wt had a significantly better outcome (OS = 26.3 vs 12.5 months, p < 0.0001), whereas in the EGFR amplification group, patients with TERTp-mut survived longer (OS = 15.8 vs 13.3 months, p = 0.05). Taken together, the absence of both EGFR amplification and TERTp-mut is associated with longer survival in patients with GBM (26.5 months for patients with IDH-wt, 36.7 months for patients with IDH mutation). CONCLUSIONS: The analysis of TERTp-mut, in combination with EGFR amplification and IDH mutation status, refines the prognostic classification of GBMs.
OBJECTIVE: To identify the prognostic significance of TERT promoter mutations (TERTp-mut) and their associations with common molecular alterations in glioblastomas (GBMs). METHODS: We sequenced the TERTp-mut in DNA from 395 GBMs and analyzed the results with their respective histology, genetic profile (IDH1 mutation, EGFR amplification, CDKN2A homozygous deletion, loss of chromosome 10, TP53 mutation), and overall survival (OS). RESULTS:TERTp-mut were found in 299 of 395 GBMs (75.7%) and were associated with an older age (median 59.6 years for TERTp-mut vs 53.6 years for TERT promoter wild type [TERTp-wt], p < 0.0001). TERTp-mut was an independent factor of poor prognosis (OS = 13.8 vs 18.4 months), in both IDH-mutated (OS = 13.8 vs 37.6 months, p = 0.022) and IDH-wt GBMs (OS = 13.7 vs 17.5 months, p = 0.006). TERTp-mut was associated with IDH-wt, EGFR amplification, CDKN2A deletion, and chromosome 10q loss, but not with MGMT promoter methylation. In the TERTp-wt group, OS was twice longer in EGFR-wt than in EGFR amplification GBMs (OS = 26.6 vs 13.3 months; p = 0.005). In the EGFR-wt group, patients with TERTp-wt had a significantly better outcome (OS = 26.3 vs 12.5 months, p < 0.0001), whereas in the EGFR amplification group, patients with TERTp-mut survived longer (OS = 15.8 vs 13.3 months, p = 0.05). Taken together, the absence of both EGFR amplification and TERTp-mut is associated with longer survival in patients with GBM (26.5 months for patients with IDH-wt, 36.7 months for patients with IDH mutation). CONCLUSIONS: The analysis of TERTp-mut, in combination with EGFR amplification and IDH mutation status, refines the prognostic classification of GBMs.
Authors: Jacob J Mandel; David Cachia; Diane Liu; Charmaine Wilson; Ken Aldape; Greg Fuller; John F de Groot Journal: J Neurooncol Date: 2016-06-07 Impact factor: 4.130
Authors: HuyTram N Nguyen; Amy Lie; Tie Li; Reshmi Chowdhury; Fei Liu; Byram Ozer; Bowen Wei; Richard M Green; Benjamin M Ellingson; He-Jing Wang; Robert Elashoff; Linda M Liau; William H Yong; Phioanh L Nghiemphu; Timothy Cloughesy; Albert Lai Journal: Neuro Oncol Date: 2017-03-01 Impact factor: 12.300